세계의 유방 생검 시장(-2025년) : 제품(바늘·테이블·분석 키트), 유형(바늘 생검(CNB·FNAB·VAB)·리퀴드 생검(CTC·ctDNA))·지침(이미지 가이드(유방 촬영술·초음파·MRI) 리퀴드 생검)·지역별
Breast Biopsy Market by Product (Needles, Tables, Assay Kit), Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy)-Global Forecasts to 2025
상품코드 : 962612
리서치사 : MarketsandMarkets
발행일 : 2020년 09월
페이지 정보 : 영문 183 Pages
US $ 4,950 ₩ 5,642,000
PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,580,000
PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,290,000
PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,399,000
PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


한글목차

세계의 유방 생검 시장 규모는 예측 기간 동안 8.6%의 CAGR로, 2020년 7억 2,500만 달러에서 2025년 10억 9,400만 달러 규모로 성장할 전망입니다. 유방암 발병률 증가, 저침습과 비침습 수술 수요 증가, 유방암 검진 프로그램 수 증가 등의 요인이 시장 성장을 견인하고 있습니다. 한편 엄격한 승인 절차, 제품 리콜 등의 과제가 향후 시장 성장을 억제하는 요인으로 예측됩니다.

제품에서는 분석 장비 부문이 기간 동안 가장 큰 성장을 보일 것으로 예측됩니다. 개별화 의료 분야에서는 유망한 액체 생검이 부문의 성공을 뒷받침할 것으로 예측됩니다. 또한 유형별로는 코어 바늘 생검 부문이 2019년 가장 큰 점유율을 차지했습니다. 감도와 높은 특이도 등의 장점에 의한 이용 증가, 기술 진보 등이 성장을 견인하고 있습니다.

세계의 유방 생검(Breast Biopsy) 시장을 조사했으며 시장 정의와 개요, 가치사슬, 신종 코로나바이러스 감염(COVID-19)과 기타 시장 영향 요인 분석, 기술 동향, 시장 규모 추이·예측, 제품 유형 지침·용도·지역/주요국 등 각종 구분별 분석, 경쟁 환경, 주요 기업 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 개요

제4장 기타 중요 고려 사항

제5장 시장 개요

제6장 시장 분석과 예측 : 제품별

제7장 시장 분석과 예측 : 유형별

제8장 시장 분석과 예측 : 지침별

제9장 시장 분석 및 예측 :용도별

제10장 시장 분석과 예측 : 지역·주요 국가별

제11장 경쟁 상황

제12장 기업 평가 매트릭스 기업 프로필

제13장 부록

NJH 20.10.13
영문 목차

영문목차

Title:
Breast Biopsy Market
by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025.

The global breast biopsy market is projected to reach USD 1,094 million by 2025 from USD 725 million in 2020, at a CAGR of 8.6% during the forecast period. The factors driving the growth of the market are growing incidence of breast cancer, increasing demand for minimally invasive and non-invasive procedures, and increasing number of breast cancer screening programs. However, stringent regulatory approval procedures, and product recalls are expected to restrain the growth of this market in the coming years.

Breast cancer is among the most common diseases affecting women in developed as well as developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe. The increasing number of breast cancer cases has forced governments across the globe to raise awareness regarding the importance of early detection of breast cancer. Thus, surge in breast cancer incidence and favorable government guidelines are expected to support market growth.

The breast biopsy market is witnessing loss of business and the trend is expected to continue till December 2020. Unfavorable changes in regulations and guidelines are hampering the growth of this industry. Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that breast cancer patients are at greater risk of COVID-19 infection than healthy adults. Thus, screening, diagnostic exams, and surgical procedures are being severely restricted or postponed at hospitals and breast centers. This is expected to cause disruption in the breast cancer diagnosis as well as treatment market.

"Assay Kits: The fastest-growing segment of breast biopsy market over the forecast period"

Based on product, the breast biopsy market is segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other products. In the past two decades, personalized medicine has increasingly been recognized for its ability to detect cancer (including breast cancer) early and accurately. Promising role of liquid biopsy in the field of personalized medicine is expected to boost the segment growth.

"Core needle biopsy: The largest sub-segment of needle breast biopsy segment"

Based on type, the breast biopsy market is segmented into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. In 2019, the needle breast biopsy held a major share of the breast biopsy market. Rising adoption of core needle biopsy by healthcare professionals due to advantages such as high sensitivity and specificity, and technological advancements are driving growth of the segment.

"Early cancer screening: The dominating application segment of breast biopsy market"

Based on application, the breast biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment accounted for largest share of the breast biopsy market in 2019. The major share of the segment is attributed to the rising incidence of breast cancer, growing awareness about early cancer screening, and development of breast cancer screening programs.

"North America: The largest share contributing reginal segment of the global breast biopsy market in 2019"

The breast biopsy market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. North America accounted for a major share of the breast biopsy market in 2019. The large share of the region can be attributed to the early adoption of newer breast biopsy technologies, ongoing technological advancements, rising breast cancer incidence, and the rapidly increasing aging population that is more prone to developing breast cancer.

A breakdown of the primary participants referred to for this report is provided below:

The major players in the market include: Hologic, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Merit Medical Systems (US), QIAGEN (Netherlands), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), Illumina, Inc. (US), and Fluxion Biosciences Inc (US), among others.

Research Coverage:

This report studies the breast biopsy market based on product, type, guidance, application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report:

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 BREAST BIOPSY MARKET, BY PRODUCT

7 BREAST BIOPSY MARKET, BY TYPE

8 BREAST BIOPSY MARKET, BY GUIDANCE

9 BREAST BIOPSY MARKET, BY APPLICATION

10 BREAST BIOPSY MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MNM view)**

*Details on Business overview, Products offered, Recent Developments, SWOT Analysis, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기